1 June 2016 - Germany's IQWiG has just completed its assessment of Lilly's Cyramza for patients with colorectal cancer or non-small-cell lung cancer.

Ramucirumab is a monoclonal antibody that reduces by blocking a receptor the formation of blood vessels and thus the blood supply to tumours. The IQWiG has been studied in two early benefit assessment of whether the drug adult patients with metastatic colorectal cancer or with locally advanced or metastatic non-small cell lung cancer (NSCLC) an additional benefit over the appropriate comparator therapies offers.

Accordingly, there is an indication of a low additional benefit for women with metastatic colorectal cancer and for men there is a clue for a lesser benefit. For patients with with NSCLC, there is a proof of a small additional benefit for those aged under 65 years but for older patients there is proof of a lesser benefit.

For more details, go to: https://www.iqwig.de/de/presse/pressemitteilungen/pressemitteilungen/ramucirumab-bei-kolorektal-und-lungenkarzinom-teils-zusatznutzen-teils-geringerer-nutzen.7374.html [German]